Consensus Solventum Corporation Mexican S.E.

Stocks

SOLV *

US83444M1018

Medical Equipment, Supplies & Distribution

End-of-day quote Mexican S.E. 2026-08-20			5-day change	1st Jan Change
1,382.00 ^MXN	0.00%		0.00%	-11.41%

08-06	Stifel Adjusts Price Target on Solventum to $100 From $90	MT
08-06	KeyBanc Adjusts Price Target on Solventum to $102 From $93	MT

Evolution of the Average Target: Solventum Corporation

Evolution of the Target Price: Solventum Corporation

Changes in Analyst Recommendations: Solventum Corporation

54b4825150.6VULFskxoXfZQ0iPC88XwaFq32Sdc-TS31jp8YV-4Po.qgpqbP8CwkKcOiLMYpler-wdkAuuFrGVl2uBo-ghtsi5OTlsv37uAp8ODQ~85bfb468bd58994dc081b0332b969592

Analysts' recommendations: Solventum Corporation

08-06	Stifel Adjusts Price Target on Solventum to $100 From $90	MT
08-06	KeyBanc Adjusts Price Target on Solventum to $102 From $93	MT
08-06	Mizuho Securities Adjusts Solventum Price Target to $113 From $100	MT
08-06	BTIG Research Adjusts Solventum Price Target to $95 From $91	MT
08-06	Jefferies & Co. Adjusts Solventum Price Target to $95 From $79	MT
08-06	Piper Sandler Adjusts Solventum Price Target to $105 From $92	MT
08-06	BMO Capital Adjusts Solventum Price Target to $84 From $81	MT
08-06	UBS Adjusts Price Target on Solventum to $101 From $95, Maintains Buy Rating	MT
08-06	Wedbush Adjusts Price Target on Solventum to $101 From $94, Maintains Outperform Rating	MT
07-28	UBS Upgrades Solventum to Buy From Neutral, Adjusts Price Target to $95 From $78	MT
07-13	BTIG Adjusts Solventum Price Target to $91 From $89, Maintains Buy Rating	MT
07-09	BMO Capital Initiates Coverage on Solventum With Market Perform Rating, $81 Price Target	MT
05-27	Goldman Sachs Adjusts Price Target on Solventum to $67 From $66, Maintains Sell Rating	MT
05-15	Solventum Seen Positioned for Meaningful Re-Rating Over Next 12 to 18 Months, Wedbush Says	MT
05-15	Wedbush Initiates Solventum at Outperform With $94 Price Target	MT
05-06	UBS Adjusts Price Target on Solventum to $78 From $82, Maintains Neutral Rating	MT
05-06	Analyst recommendations: AMD, KKR, PayPal Holdings, Arista Networks, and TransDigm Group.
04-27	KeyBanc Adjusts Price Target on Solventum to $92 From $99, Maintains Overweight Rating	MT
04-17	Piper Sandler Adjusts Solventum PT to $92 From $98, Maintains Overweight Rating	MT
04-13	BTIG Research Adjusts Solventum Price Target to $89 From $100, Maintains Buy Rating	MT
04-08	Goldman Sachs Adjusts Solventum Price Target to $66 From $72, Maintains Sell Rating	MT
03-24	Rothschild & Co Redburn Initiates Solventum at Sell, With $60 Price Target	MT
03-02	UBS Adjusts Solventum Price Target to $82 From $79, Maintains Neutral Rating	MT
02-27	KeyBanc Adjusts Price Target on Solventum to $99 From $97, Maintains Overweight Rating	MT
02-27	Wells Fargo Adjusts Price Target on Solventum to $83 From $86, Maintains Equalweight Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ABBOTT LABORATORIES					+3.05%
	MEDTRONIC PLC					+5.45%
	CENCORA, INC.					+16.12%
	HOYA CORPORATION					+22.73%
	BECTON, DICKINSON AND COMPANY					+1.26%
	DEXCOM, INC.					+1.93%
	MEDLINE INC.					+30.23%
	WEST PHARMACEUTICAL SERVICES, INC.					+14.63%
	TERUMO CORPORATION					+21.96%
	Average					+13.04%
	Weighted average by Cap.					+8.94%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

89.57USD

Average target price

93.92USD

Spread / Average Target

+4.86%

High Price Target

113.00USD

Spread / Highest target

+26.16%

Low Price Target

70.00USD

Spread / Lowest Target

-21.85%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

KeyBanc Capital Markets
Stifel Nicolaus
Wedbush
UBS
BMO Capital
Piper Sandler
Jefferies & Co.
BTIG
Mizuho Securities
Goldman Sachs
Rothschild & Co Redburn
Wells Fargo Securities
Argus
Morgan Stanley
Wolfe Research